2020
Awareness about and willingness to use long-acting injectable pre-exposure prophylaxis (LAI-PrEP) among people who use drugs
Shrestha R, DiDomizio EE, Kim RS, Altice FL, Wickersham JA, Copenhaver MM. Awareness about and willingness to use long-acting injectable pre-exposure prophylaxis (LAI-PrEP) among people who use drugs. Journal Of Substance Use And Addiction Treatment 2020, 117: 108058. PMID: 32811633, PMCID: PMC7438607, DOI: 10.1016/j.jsat.2020.108058.Peer-Reviewed Original ResearchConceptsPre-exposure prophylaxisInjectable pre-exposure prophylaxisLAI-PrEPOral pre-exposure prophylaxisLong-term side effectsSelf-reported HIV risk behaviorsBangkok Tenofovir StudyEvidence-based HIVHigh-risk PWUDImportant key populationHIV-negative peopleOpioid use disorderHIV risk behaviorsHIV prevention effortsAddiction treatment programsDaily PrEPOral PrEPAdherence challengesIndependent correlatesFemale sexClinical trialsHIV preventionIndependent factorsSide effectsUse disorders
2017
Implementing and scaling up HCV treatment services for people who inject drugs and other high risk groups in Ukraine: An evaluation of programmatic and treatment outcomes
Mazhnaya A, Meteliuk A, Barnard T, Zelenev A, Filippovych S, Altice FL. Implementing and scaling up HCV treatment services for people who inject drugs and other high risk groups in Ukraine: An evaluation of programmatic and treatment outcomes. International Journal Of Drug Policy 2017, 47: 187-195. PMID: 28811159, PMCID: PMC5918282, DOI: 10.1016/j.drugpo.2017.07.023.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntiviral AgentsCoinfectionFemaleGenotypeHealth ServicesHepacivirusHepatitis CHIV InfectionsHumansInterferon-alphaMalePolyethylene GlycolsProgram DevelopmentProgram EvaluationRecombinant ProteinsRibavirinRisk FactorsSex FactorsSofosbuvirSubstance Abuse, IntravenousSustained Virologic ResponseTreatment OutcomeUkraineYoung AdultConceptsSustained virologic responseHCV treatmentRisk groupsSVR ratesMedical recordsDirect acting antiviral medicationsComparable SVR ratesHCV genotype 3HCV prevalence estimatesHCV treatment servicesActing antiviral (DAA) medicationsCombination of sofosbuvirHigh-risk groupPatient-level outcomesProportion of participantsCommunity-based settingsDAA treatmentVirologic responseAntiviral medicationsHIV characteristicsHCV genotypesIndependent correlatesSVR dataFemale sexGenotype 3
2014
Emergency Department Use among HIV-Infected Released Jail Detainees
Boyd AT, Song DL, Meyer JP, Altice FL. Emergency Department Use among HIV-Infected Released Jail Detainees. Journal Of Urban Health 2014, 92: 108-135. PMID: 25331820, PMCID: PMC4338130, DOI: 10.1007/s11524-014-9905-4.Peer-Reviewed Original ResearchConceptsHIV primary careEmergency department useED visitsPrimary careHIV careED useDepartment useDrug severitySubstance useCox proportional hazards regressionUnique ED visitsProportional hazards regressionMultivariate negative binomial regressionHIV/AIDSRecent substance useHealth care continuityPrimary outcomeHazards regressionCare continuityFemale sexMedical recordsJail detentionJail detaineesNegative binomial regressionPotential covariates